| Title |
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
|
|---|---|
| Published in |
Targeted Oncology, April 2011
|
| DOI | 10.1007/s11523-011-0177-6 |
| Pubmed ID | |
| Authors |
Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, Sandrine Faivre |
| Abstract |
In the quest for personalized medicine, only a few biological parameters are routinely used to select patients prior to the initiation of anticancer targeted therapies, including mTOR inhibitors. Identifying biological factors that may predict efficacy or resistance to mTOR inhibitors represents an important challenge since rapalogs may exert antitumor effects through multiple mechanisms of action. Despite the fact that no such a factor is currently available, several molecular patterns are emerging, correlating with sensitivity and/or resistance to rapalogs. While activation of the phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, overexpression of cyclin D1, and functional apoptosis seem to sensitize tumor cells to rapalogs, Bcl2 overexpression or KRAS mutations are reported to be associated with resistance to mTOR inhibitors in several preclinical models. Translational research aimed at validating those parameters in clinical trials is ongoing. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 26% |
| Other | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Bachelor | 3 | 10% |
| Student > Master | 3 | 10% |
| Other | 4 | 13% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 11 | 35% |
| Medicine and Dentistry | 6 | 19% |
| Biochemistry, Genetics and Molecular Biology | 5 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Design | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 7 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2013.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from Targeted Oncology
#125
of 551 outputs
Outputs of similar age
#40,295
of 110,109 outputs
Outputs of similar age from Targeted Oncology
#3
of 4 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 551 research outputs from this source. They receive a mean Attention Score of 2.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 110,109 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.